A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With Specific Advanced Cancers.

Stopped considering the limited clinical activity observed with LTT462, the decision was made to not open the dose expansion phase of the study

Conditions

• Ovarian Neoplasms
• Non-Small-Cell Lung Carcinoma
• Melanoma
• Other Solid Tumors

Interventions

• DRUG: LTT462

Sponsor

Novartis Pharmaceuticals